If Mills is able to shift the emphasis from prescription...

If Mills is able to shift the emphasis from prescription medication to OTC and get stuff on the shelves at the supermarket and pharmacy, as well as promote the prescription line the market will respond.

Management of AC8 has been stagnating since Ido Kanyon decided he had to go back to the US. They don't appear to have done anything at all other than this merger.

SeaHunt may be right but the chances are with CP1's vet treatments and a concerted effort on Neuvis both OTC and prescription we might see $1 by the FY 21/22.